Aktualisiertung19.10.2021. Der Aufklärungsbogen in einfacher Sprache kann in zahlreichen weiteren Sprachen heruntergeladen werden kann: Albanisch, Arabisch,Bulgarisch, Dari, Englisch, Französisch, Kroatisch, Pashtu, Persisch, Polnisch, Rumänisch, Russisch, Serbisch, Spanisch, Tigrinisch, Türkisch, Urdu, Vietnamesisch https://www.rki.de/DE/Content/Infekt/Impfen/Materialien/COVID-19-Aufklaerungsbogen-Tab.htm

Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets.�

Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine methodology issues there are still insufficient data to make a recommendation, in which case different options for approaching VE evaluations are presented

The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. The COVID-19 vaccine tracker: Provides summary tables of COVID-19 vaccine candidates in both clinical and pre-clinical development; Provides analysis and visualization for several COVID-19 vaccine candidate categories; Tracks the progress of each vaccine from pre-clinical, Phase 1, Phase 2 through to Phase 3 efficacy studies and including Phase 4 registered as interventional studies; Provides links to published reports on safety, immunogenicity and efficacy data of the vaccine candidates; Includes information on key attributes of each vaccine candidate and Allows users to search for COVID-19 vaccines through various criteria such as vaccine platform, schedule of vaccination, route of administration, developer, trial phase and clinical endpoints. The database is updated regularly - twice a week (Tuesday and Friday, 17:00 CET)

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below

mRNA technologies. What is their future and scope, and what are the challenges that countries might face in rolling them out? Hello and welcome to Science in5. I'm Vismita Gupta-Smith. We are talking to Dr.Soumya Swaminathan today. Soumya, talk to us about mRNA technologies. What is the future

first issued 18 August 2022

CONVIDECIA is based on a modified human adenovirus that expresses the spike S protein of SARS-CoV-2. It is administered as a single dose.

Los datos preliminares de eficacia se infirieron mediante un enfoque de “inmunogenicidad puente”, en el que los títulos neutralizantes obtenidos después de la vacuna en niños y niñas de 5 a 11 años se compararon con los títulos obtenidos en adolescentes de 16 a 25 años (en quienes se había evaluado la eficacia).Entre los participantes sin evidencia de infección previa por SARS-CoV-2, hubo 3 casos de COVID-19 entre los 1.305 receptores de vacuna a partir de los 7 días de la segunda dosis y 16 entre los 663 receptores de placebo

El siguiente manual se continuará actualizando, de ser necesario, a medida que se disponga de nueva información.